PMID- 19571387
OWN - NLM
STAT- MEDLINE
DCOM- 20091008
LR  - 20190720
IS  - 0918-6158 (Print)
IS  - 0918-6158 (Linking)
VI  - 32
IP  - 7
DP  - 2009 Jul
TI  - Anti-clastogenic effect of magnolol-containing Hange-koboku-to, Dai-joki-to, 
      Goshaku-san, and Magnoliae Cortex on benzo(a)pyrene-induced clastogenicity in 
      mice.
PG  - 1209-14
AB  - Magnolol was previously shown to inhibit genotoxicity induced by environmental 
      mutagens both in vitro and in vivo. Here, we investigate the effects of the 
      magnolol-containing kampo (traditional) medicines Hange-koboku-to, Dai-joki-to, 
      and Goshaku-san, as well as Magnoliae Cortex, on the clastogenesis induced by 
      benzo(a)pyrene (B(a)P) using the mouse micronucleus test. The mice were first 
      treated with a single intraperitoneal injection of B(a)P, followed by a single 
      oral dose of Hange-koboku-to, Dai-joki-to, Goshaku-san, or Magnoliae Cortex. 
      Peripheral blood specimens were prepared 48 h after B(a)P administration and 
      analyzed using the acridine orange (AO) technique. The anti-clastogenic 
      mechanisms employed by the kampo medicines and Magnoliae Cortex were also 
      investigated by evaluating in vivo CYP1A1 activity using the zoxazolamine 
      paralysis test. Results show that Hange-koboku-to, Dai-joki-to, and Magnoliae 
      Cortex, which contain high levels of magnolol, significantly inhibited the 
      clastogenesis induced by B(a)P and sufficiently inhibited in vivo CYP1A1 
      activity. In contrast, Goshaku-san, which contains low levels of magnolol, had 
      little inhibitory effect on clastogenicity and in vivo CYP1A1 activity. These 
      findings suggest that magnolol is a major contributor to the inhibition of 
      B(a)P-induced clastogenesis, and that kampo medicines exert significant 
      anti-clastogenic effects.
FAU - Saito, Junichiro
AU  - Saito J
AD  - Drug Safety Research Laboratories, Astellas Pharma Inc. 
      junichiroh.saitho@jp.astellas.com
FAU - Fukushima, Hiroko
AU  - Fukushima H
FAU - Nagase, Hisamitsu
AU  - Nagase H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Antimutagenic Agents)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Lignans)
RN  - 0 (Mutagens)
RN  - 001E35HGVF (magnolol)
RN  - 3417WMA06D (Benzo(a)pyrene)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP1A1)
SB  - IM
MH  - Animals
MH  - Antimutagenic Agents/isolation & purification/*pharmacology
MH  - Benzo(a)pyrene/*toxicity
MH  - Biphenyl Compounds/isolation & purification/*pharmacology
MH  - Cytochrome P-450 CYP1A1/antagonists & inhibitors
MH  - Dose-Response Relationship, Drug
MH  - Drugs, Chinese Herbal/isolation & purification/*pharmacology
MH  - Lignans/isolation & purification/*pharmacology
MH  - Magnolia/*chemistry
MH  - *Medicine, Kampo
MH  - Mice
MH  - Mice, Inbred ICR
MH  - Micronucleus Tests
MH  - Mutagens/*toxicity
MH  - Plant Bark/chemistry
EDAT- 2009/07/03 09:00
MHDA- 2009/10/09 06:00
CRDT- 2009/07/03 09:00
PHST- 2009/07/03 09:00 [entrez]
PHST- 2009/07/03 09:00 [pubmed]
PHST- 2009/10/09 06:00 [medline]
AID - JST.JSTAGE/bpb/32.1209 [pii]
AID - 10.1248/bpb.32.1209 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2009 Jul;32(7):1209-14. doi: 10.1248/bpb.32.1209.